AI for Early Identification of Breast Cancer – Efficient and Accurate Diagnosis

By Michael Awood

September 15, 2023

Breast cancer is the second leading cause of cancer death in women. Early identification can ease this to ensure early access to treatment. Developed nations have vast mammography screening programs, but interpreting the images is still hard. The accuracy of cancer detection varies widely among experts, and the potential for improvement is significant. False positives can lead to patient anxiety, unnecessary follow-up, and invasive diagnostic procedures. Sometimes screening cannot identify cancers until they are more advanced and less amenable to treatment.

Artificial Intelligence (AI) can overcome this challenge. Studies show it can outperform human experts in many medical image analysis tasks. This leads us to evaluate AI’s potential to augment the early identification process of breast cancer through high-quality images.

Researchers recently tested a new AI system that predicts breast cancer using large datasets from the UK and the USA. The system outperformed radiologists in daily predictions, according to the researchers. They confirmed these observations with an independently conducted reader study. The system could generalize across different screening populations and settings without additional training data.

The AI system might reduce the workload involved in the double-reading process used in the UK while preserving the standard of care. The system could also provide automated, immediate feedback in the screening setting. This technology can sort cases at the risk level, making it possible to screen efficiently even with a limited workforce.

Overall, the AI was better than radiologists at identifying breast cancer. These results held across two large datasets that represent different screening populations and practices. However, the optimal use of the AI system within clinical workflows remains to be determined.

Cover image taken from the journal article. 

Reference url

Recent Posts

access to medicines
         

Quantifying EU Medicine Access Challenges

🔍 Are we creating a healthcare system that truly works for everyone?

Recent findings from EFPIA shed light on alarming inequities in access to medicines across Europe, showing that only 46% of approved drugs are available to patients this year. With significant delays affecting smaller markets and critical cancer treatments, this article explores the systemic barriers at play and innovative solutions proposed to ensure fair access.

Dive into the full article to uncover how we can collectively shape a more equitable healthcare landscape.

#SyenzaNews #healthcare #MarketAccess

UK Medicine Payment Rates
      

Revitalizing Innovation: The Impact of UK Medicine Payment Rates

💡 Are the UK’s medicine payment rates stifling innovation in life sciences?

Recent analysis reveals that the staggering 23.5% payment rate for pharmaceuticals is not just limiting NHS spending but also curtailing R&D investments, delaying new drug launches, and threatening workforce stability. If we can lower these rates to below 10%, we could unleash significant growth and restore the UK’s competitive edge in the global life sciences landscape.

Discover the critical insights and recommendations that could reshape the future of healthcare in the UK.

#SyenzaNews #healthcarepolicy #innovation

Blinatumomab benefit assessment
            

Blinatumomab Benefit Assessment for ALL and Health Economics

🚀 How does a groundbreaking therapy change the landscape of acute lymphoblastic leukemia treatment?

The recent benefit assessment of Blinatumomab by the German Federal Joint Committee reveals critical insights into its potential as a consolidation therapy for adults with Philadelphia chromosome-negative B-cell precursor ALL. With its orphan drug status promising automatic benefits, the article explores the implications of its high cost and economic impacts, shedding light on the balance needed between innovation and sustainability in healthcare.

Jump into the full analysis to understand how this could impact clinical practice and health economics.

#SyenzaNews #HealthEconomics #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.